Latest Breaking News On - Use investigational new drug - Page 1 : comparemela.com

Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil

Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

United statesBaden wubergDorian bevecAdvita lifescience gmbhJack weinsteinAdvita lifescience gmbRelief therapeutics holdingsNeurorx incSwiss exchangeAcute respiratory distress syndromeCheckpoint inhibitor induced pneumonitisChronic beryllium diseaseUse investigational new drugExpanded access protocolVita lifescience gmbhUnited states wire group

Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM

Press release content from Accesswire. The AP news staff was not involved in its creation.

United statesRaghuram ram selvarajuChris brownHolding ag raghuram ram selvarajuRelief therapeutics holdingsGlobal yieldNeurorx incSwiss exchangeShare subscription facilityUse investigational new drugExpanded access protocolAnne henneckeBrittney sojevaCorporate newsCoronavirus pandemicProduction facilities

Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope

Search jobs 20-Jan-2021 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Mergers & Acquisitions 20.01.2021 / 07:00 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil Geneva, Switzerland, and Gundelfingen, Germany, January 20, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ( Relief ), a biopharmaceutical company with its lead compound RLF-100 TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH (

United statesBaden wubergAnne hennecke brittney sojevaDorian bevecWolfgang hoppeAdvita lifescience gmbhRaghuram ram selvarajuJack weinsteinAdvita lifescience gmbMc servicesNeurorx incSwiss exchangeHoldings ag keyAdvita sign binding term sheetAcquire all sharesExpand scope

Relief Therapeutics Holding AG: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil

Relief Therapeutics Holding AG: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil Relief ), a biopharmaceutical company with its lead compound RLF-100 TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH ( AdVita ), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases, today announced the companies have signed a binding term sheet for Relief to acquire all shares of AdVita in exchange for EUR 25 million of Relief common shares, plus possible future contingent milestone payments of up to EUR 20 million. The closing of the transaction is subject to customary closing conditions as well as legal and securities regulatory approvals and is expected to occur in Q2 2021.

United statesBaden wubergAnne hennecke brittney sojevaDorian bevecWolfgang hoppeAdvita lifescience gmbhRaghuram ram selvarajuJack weinsteinAdvita lifescience gmbMc servicesRelief therapeutics holdingsNeurorx incSwiss exchangeAcute respiratory distress syndromeCheckpoint inhibitor induced pneumonitisChronic beryllium disease

Relief Appoints Chris L J J Stijnen as Chief Commercial Officer

Share: Relief or the Company ), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ( Chris ) L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets. Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company s portfolio in various international subsidiaries between 2005 and March 2020. Most recently he was VP Product & Portfolio Strategy and Interim Head Commercial Strategy and Capabilit

United statesNew jerseyZuid hollandAnne hennecke brittney sojevaChristiaan chrisRaghuram ram selvarajuBristol myers squibbMc servicesErasmus university rotterdamMerck coSwiss exchangeRelief therapeutics holdingsPlough corporationChief commercial officerPortfolio strategyInterim head commercial strategy